Intel stock spikes after report of possible US government stake
LONDON - Investment management corporation BlackRock (NYSE:BLK), Inc. has reported a holding in Mural Oncology plc, a company currently involved in a takeover process. As of April 16, 2025, BlackRock’s position in Mural Oncology includes both ownership and short positions, signaling its financial interest in the company’s securities.
Specifically, BlackRock has disclosed ownership of 241,125 ordinary shares, representing approximately 1.39% of Mural Oncology, alongside short positions amounting to 130,899 shares, or 0.75%. Additionally, the firm holds cash-settled derivatives equivalent to 71,756 shares, about 0.41% of the company. In total, BlackRock’s combined interests and short positions in Mural Oncology represent 1.39% and 1.17%, respectively.
The disclosure, mandated by the rules of the Irish Takeover Panel, comes amidst no reported dealings by BlackRock in any other party to the offer. The report also includes a recent sale of 2,075 Mural Oncology ordinary shares at a price of USD 2.4200 per unit.
Further details on BlackRock’s dealings include a stock on loan transaction involving 61,789 shares and transfers of shares in and out of BlackRock’s control. These transactions reflect routine adjustments to the firm’s holdings and do not necessarily indicate strategic changes in BlackRock’s investment stance.
The report does not indicate any indemnity or dealing arrangements that could serve as an inducement to deal or refrain from dealing in the securities mentioned. BlackRock has also confirmed that no supplemental form is attached to this disclosure.
This disclosure is part of the regulatory process in situations where interests in relevant securities represent 1% or more, providing transparency in the context of takeover activities. The investment community often scrutinizes such disclosures for insights into institutional investor behavior and potential market movements.
The information is based on a press release statement and is intended to present the facts of BlackRock’s disclosed positions in Mural Oncology without speculation or promotional commentary.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.